Literature DB >> 11302729

Expression of survivin in HTLV-I-infected T-cell lines and primary ATL cells.

N Mori1, Y Yamada, T Hata, S Ikeda, Y Yamasaki, M Tomonaga, N Yamamoto.   

Abstract

Human T-cell leukemia virus type I (HTLV-I) is the etiological agent of adult T-cell leukemia (ATL), although the precise mechanisms involved in the transformation process have not yet been defined. Deregulated inhibition of apoptosis may facilitate the insurgence of leukemia. Survivin is an inhibitor of apoptosis and considered to play a role in oncogenesis. We investigated the expression of survivin in HTLV-I-infected T-cell lines and primary ATL cells. Northern blot analysis showed expression of survivin transcript in all 9 HTLV-I-positive T-cell lines. High survivin expression levels were detected in primary cells of patients with acute-type ATL, but no such expression was noted in the cells of chronic-type ATL or normal peripheral blood mononuclear cells. Treatment of an HTLV-I-infected T-cell line, MT-1, with survivin specific antisense oligonucleotide resulted in reduced cell growth. Our results suggest that expression of survivin may play an important role in the development and pathogenesis of ATL. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11302729     DOI: 10.1006/bbrc.2001.4708

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

Review 1.  Survivin and leukemia.

Authors:  Xiu Li Cong; Zhong Chao Han
Journal:  Int J Hematol       Date:  2004-10       Impact factor: 2.490

2.  Complex cell cycle abnormalities caused by human T-lymphotropic virus type 1 Tax.

Authors:  Liangpeng Yang; Naoe Kotomura; Yik-Khuan Ho; Huijun Zhi; Sandra Bixler; Michael J Schell; Chou-Zen Giam
Journal:  J Virol       Date:  2011-01-05       Impact factor: 5.103

Review 3.  T-cell control by human T-cell leukemia/lymphoma virus type 1.

Authors:  Genoveffa Franchini; Risaku Fukumoto; Jake R Fullen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

4.  Emodin and DHA potently increase arsenic trioxide interferon-alpha-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1.

Authors:  Megan Brown; Marcia Bellon; Christophe Nicot
Journal:  Blood       Date:  2006-10-31       Impact factor: 22.113

5.  Clinical relevance of survivin as a biomarker in neoplasms, especially in adult T-cell leukemias and acute leukemias.

Authors:  Kazuyuki Sugahara; Akiko Uemura; Hitomi Harasawa; Hiroshi Nagai; Yoichi Hirakata; Masao Tomonaga; Kenn Murata; Hiroshi Sohda; Toru Nakagoe; Sin-ichi Shibasaki; Yasuaki Yamada; Shimeru Kamihira
Journal:  Int J Hematol       Date:  2004-07       Impact factor: 2.490

6.  Involvement of glutathione as a mechanism of indirect protection against spontaneous ex vivo apoptosis associated with bovine leukemia virus.

Authors:  Teresa Sanchez Alcaraz; Pierre Kerkhofs; Michal Reichert; Richard Kettmann; Luc Willems
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

7.  Do Bcl-2 and survivin help distinguish benign from malignant B-cell lymphoid aggregates in bone marrow biopsies?

Authors:  Amish M Gandhi; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

Review 8.  Role of survivin and its splice variants in tumorigenesis.

Authors:  F Li
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

9.  IL-10-mediated signals act as a switch for lymphoproliferation in Human T-cell leukemia virus type-1 infection by activating the STAT3 and IRF4 pathways.

Authors:  Leila Sawada; Yoshiko Nagano; Atsuhiko Hasegawa; Hikari Kanai; Kai Nogami; Sayaka Ito; Tomoo Sato; Yoshihisa Yamano; Yuetsu Tanaka; Takao Masuda; Mari Kannagi
Journal:  PLoS Pathog       Date:  2017-09-14       Impact factor: 6.823

Review 10.  Role of Tax protein in human T-cell leukemia virus type-I leukemogenicity.

Authors:  Inbal Azran; Yana Schavinsky-Khrapunsky; Mordechai Aboud
Journal:  Retrovirology       Date:  2004-08-13       Impact factor: 4.602

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.